Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Head & Neck 1

Conditions

Melanoma 3Neoplasms 2HIV Infections 2Carcinoma, Hepatocellular 2Acquired Immunodeficiency Syndrome 2Stomach Ulcer 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma, Kaposi 1Sarcoma 1Muscle Neoplasms 1Hepatitis B 1Duodenal Ulcer 1Adenoviridae Infections 1AIDS-Related Complex 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Melanoma × Tumor Necrosis Factor-alpha × Clear all
NCT05222932 2025-08-07

AVENTIL

TILT Biotherapeutics Ltd.

Phase 1 Active not recruiting
15 enrolled
DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Melanoma

NCT00003789 2013-07-16

Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg

National Cancer Institute (NCI)

Phase 3 Completed
216 enrolled
Dermatologic

Melanoma

NCT00001296 2008-03-04

A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma

National Institutes of Health Clinical Center (CC)

Phase 3 Completed
122 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡